公开(公告)号：US11365196B2

公开(公告)日：2022-06-21

申请号：US16488899

申请日：2018-02-27

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaofeng Xu ,  Jiabing Wang ,  Lieming Ding ,  Xiangyong Liu

IPC: C07D471/14 ,  A61K31/519 ,  A61P35/00 ,  C07D519/00

Abstract: An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like.

公开(公告)号：US09688687B2

公开(公告)日：2017-06-27

申请号：US14896706

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Shaojing Hu ,  Wei Long ,  Fei Wang ,  Yinxiang Wang ,  Lieming Ding

IPC: C07D491/056 ,  A61K31/519 ,  A61K45/06 ,  C30B7/00 ,  C30B7/14 ,  C30B29/54

CPC classification number: C07D491/056 ,  A61K31/519 ,  A61K45/06 ,  C07B2200/13 ,  C30B7/00 ,  C30B7/14 ,  C30B29/54

Abstract: Disclosed is Icotinib phosphate (i.e., the compound of Formula (I)) and polymorph forms thereof, and methods of preparing and using them.

公开(公告)号：US09611272B2

公开(公告)日：2017-04-04

申请号：US14896992

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Shaojing Hu ,  Wei Long ,  Fei Wang ,  Yinxiang Wang ,  Lieming Ding

IPC: A61K31/519 ,  A61K45/06 ,  C07D491/056 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D491/056 ,  A61K9/20 ,  A61K9/48 ,  A61K31/519 ,  A61K45/06

Abstract: The present invention relates to the polymorphic forms of the compound of Formula I, preparation thereof and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition.

公开(公告)号：US12187713B2

公开(公告)日：2025-01-07

申请号：US17427112

申请日：2020-01-20

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： Yiqian Wang ,  Yao Zhang ,  Bang Fu ,  Jiabing Wang ,  Lieming Ding

IPC: C07D413/14 ,  C07D451/02 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04

Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20230203055A1

公开(公告)日：2023-06-29

申请号：US17997328

申请日：2021-04-27

Applicant: Betta Pharmaceuticals Co., LTD

Inventor： Hao Wu ,  Xiaoping Chen ,  Jun Yu ,  Yuan Lu ,  Jiangqi He ,  Wei Wang ,  Bo Zhan ,  Boyan Li ,  Yunlai Zhang ,  Dong Wang ,  Xiujun Xie ,  Xiaoguan Zhu ,  Hong Lan ,  Jiabing Wang ,  Lieming Ding

IPC: C07D491/052 ,  C07D491/044 ,  C07D491/147 ,  C07D519/00 ,  C07D487/04 ,  C07D498/22 ,  C07D471/04

CPC classification number: C07D491/052 ,  C07D471/04 ,  C07D487/04 ,  C07D491/044 ,  C07D491/147 ,  C07D498/22 ,  C07D519/00 ,  C07B2200/05

Abstract: The present invention relates to a novel compound (formula I), which has cancer treatment activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound.

公开(公告)号：US20230062486A1

公开(公告)日：2023-03-02

申请号：US17757688

申请日：2020-12-18

Applicant: Betta Pharmaceuticals Co., LTD

Inventor： Hao Wu ,  Xiaoping Chen ,  Yuan Lu ,  Jun Yu ,  Xiujun Xie ,  Jiangqi He ,  Shuibiao Fu ,  Qi Shen ,  Letian Zhang ,  Xiaoguan Zhu ,  Hong Lan ,  Jiabing Wang ,  Lieming Ding

IPC: C07D487/04 ,  A61K31/4985 ,  A61P35/00

Abstract: Provided are compounds of formula (I), which have KRAS mutation tumor regulating activity. Also provided are a method for providing these compounds and a pharmaceutical composition comprising the same.

公开(公告)号：US09505774B2

公开(公告)日：2016-11-29

申请号：US14896707

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Shaojing Hu ,  Wei Long ,  Fei Wang ,  Yinxiang Wang ,  Lieming Ding

IPC: C07D491/056 ,  A61K31/519 ,  C07C57/145 ,  A61K45/06 ,  A61K31/517

CPC classification number: C07D491/056 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07B2200/13 ,  C07C57/145 ,  A61K2300/00

Abstract: Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them.